Chardan upgraded Korro Bio (KRRO) to Buy from Neutral with a $15 price target following the analyst day. The company says the company has “turned the page.” It cites the “strong” KRRO-121 preclinical data for the upgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Piper upgrades Korro to Overweight on bullish KRRO-121 view
- Korro Bio upgraded to Overweight from Neutral at Piper Sandler
- Midday Fly By: AT&T reports Q4 beat, Amazon cuts 16,000 jobs
- Oppenheimer upgrades Korro Bio to Outperform as KRRO-121 offers fresh story
- Korro Bio upgraded to Outperform from Perform at Oppenheimer